Results and clinical implications of the CAPARES trial

The Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES) is a multice ntre, double-blind, placebo controlled restenosis trial investigating the e ffect of amlodipine on angiographic and clinical endpoints in patients unde rgoing routine percutaneous transluminal coronary angioplasty (PTCA) for st able angina pectoris. A total of 635 patients were randomized to amlodipine or placebo two weeks before MCA and were followed for four months after PT CA. There were 451 nonstented patients who completed the study with angiogr aphic follow-up. Quantitative coronary angiography revealed that the loss i n minimal luminal diameter from immediately after PTCA to the four-month fo llow-up was unaffected by amlodipine treatment. However, the incidence of r epeat PTCA and composite clinical events were significantly lower in patien ts treated with amlodipine.